AngioGenex, Inc. (fka AGGX)

[e-ore]

AGGX has patented technology here

"Uncovering new functions of a gene implicated in cancer growth opens new therapeutic possibilities
Date:
April 29, 2015
Source:
Weill Cornell Medical College
Summary:
For the first time, researchers have shown that a gene previously implicated in blood vessel formation during embryonic development and tumor growth also induces immune suppression during tumor development. This finding opens the door for new therapeutic approaches and vaccine development in treating patients with melanoma and other advanced-staged cancers."

http://www.sciencedaily.com/releases/2015/04/150429145458.htm

AngioGenex is a biopharmaceutical company formed to pursue the discovery and development of proprietary products for the treatment, diagnosis and prognosis of cancer. While there are numerous companies that have the same objective, none have the unique, patented technology that is being exploited by AngioGenex.
The target of the AngioGenex drug discovery effort is a previously unrecognized biological process necessary to support tumor growth that emerged from one of the most famous cancer laboratories, Memorial Sloan Kettering Cancer Center, NYC. Dr. Robert Benezra, a distinguished member of this institute, discovered that certain genes (Id genes) are actively involved in fetal growth and can be inappropriately activated in the adult to support the growth and spread of tumors. He showed that tumor growth is markedly inhibited if these genes or their proteins are even partially inactivated.
In collaboration with Dr. Benezra, AngioGenex has successfully pursued the discovery and development of molecules that inhibit the Id proteins and block tumor growth in animals. This research confirms that the Id genes are the controlling, master genes, in a unique and previously unknown process that is required for the growth and spread of tumors. A profound inhibition of tumor growth is demonstrated in animals that either have the Id genes deleted by genetic manipulation or are treated with an anti-Id drug (See Figure below).
An important finding is that the Id genes are structurally almost identical in humans as in animals suggesting that the anti-tumor effects of Id drug observed in animals will also occur in humans.

http://www.angiogenex.com/technology.html

http://www.angiogenex.com/patents.html